Rentschler Biopharma, a Germany-based biopharmaceuticals manufacturer with a facility in Milford, is set to produce a novel blood coagulation treatment developed by Netherlands-based VarmX, with the hopes to support future commercialization.
Rentschler Biopharma’s most recent agreement with VarmX follows four years of collaboration on the blood coagulation drug, known as VMX-C001. The treatment is used in preparation for time-sensitive surgery for patients on blood thinners experiencing severe bleeding, according to a Thursday press release from Rentschler.
VMX-C001, which will be produced at Rentschler’s Milford site, works by bypassing blood thinners’ anticoagulant effects, reestablishing the body’s ability to coagulate blood to reduce excessive bleeding during surgery.
“We are honored to continue our collaboration with VarmX, which reflects exactly what Rentschler Biopharma stands for: high‑impact technical expertise, long‑term partnership grounded in trust, and tailored solutions that bring breakthrough therapies to patients,” Benedikt von Braunmühl, Rentschler CEO, said in the press release.
With this partnership, Rentschler will produce the clinical supply needed of VMX-C001 in order to perform a Phase 3 clinical trial: the last stage of clinical trials before a drug is moved onto the FDA approval process, in which the medication’s efficacy is compared to current available treatments.
The companies expect to begin a global Phase 3 trail early this year.
Rentschler reports it is expected that 30 million patients throughout the U.S., Europe, and Japan will be using blood thinners by 2030, with 30,000 of them needing emergency surgery caused by life-threatening bleeding each week.
“We’re pleased to extend our partnership with Rentschler Biopharma as we drive VMX-C001 towards becoming a new treatment option for the substantial number of patients on FXa DOACs who need emergency surgery,” John Glasspool, VarmX CEO said in the release.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare, manufacturing, and higher education industries.
